Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults.
Hodgkin lymphoma
Novel therapeutics
Pediatrics
Journal
Best practice & research. Clinical haematology
ISSN: 1532-1924
Titre abrégé: Best Pract Res Clin Haematol
Pays: Netherlands
ID NLM: 101120659
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
01
02
2023
accepted:
01
02
2023
entrez:
12
3
2023
pubmed:
13
3
2023
medline:
15
3
2023
Statut:
ppublish
Résumé
Advances in the management of Hodgkin lymphoma in children, adolescents and young adult have resulted in survival outcomes exceeding 90%. The risk of late toxicity, however, remains a significant concern for survivors of HL and the focus of modern trials have been to advance cure rates while reducing long term toxicity. This has been accomplished through response-adapted treatment approaches and the incorporation of novel agents, many of which target the unique interaction between the Hodgkin and Reed Sternberg cells and the tumor microenvironment. In addition, an improved understanding of prognostic markers, risk stratification, and the biology of this entity in children and AYAs may allow us to further tailor therapy. This review focuses on the current management of HL in the upfront and relapsed settings, recent advances in novel agents that target HL and the tumor microenvironment, and promising prognostic markers that may help guide the future management of HL.
Identifiants
pubmed: 36907636
pii: S1521-6926(23)00006-3
doi: 10.1016/j.beha.2023.101445
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101445Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest The authors have no conflicts of interests.